Muhammad Anwar, MD
Pulmonary Disease · Sherman Oaks, CANPI 1497769145
Payments from drug & device makers
Across 7 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$148
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
- Philips North America LLC$36
- Mallinckrodt Enterprises LLC$29
- Mallinckrodt Hospital Products Inc.$28
- Phadia US Inc.$18
- plus $17 from 1 others
What the payments were for
- Food & beverage$312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 1 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $36 |
| Philips North America LLC | 1 | $36 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Phadia US Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ovitex$148
How this compares
$312 in reported general payments places this provider in the 30th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,248 |
| Ipratropium Bromide | 112 | $1,779 |
| Albuterol Sulfate | 116 | $1,638 |
| Cinacalcet Hcl | 12 | $1,491 |
| Levalbuterol Hcl | 20 | $1,009 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 30 | $782 |
| Chlorhexidine Gluconate | 68 | $666 |
| Atorvastatin Calcium | 43 | $598 |
| Nifedipine ErNifedipine | 12 | $453 |
| Metformin Hcl | 21 | $258 |
| Memantine Hcl | 11 | $227 |
| Levothyroxine Sodium | 12 | $217 |
| Carvedilol | 12 | $177 |
| Levetiracetam | 13 | $149 |
| Pantoprazole Sodium | 13 | $123 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Sherman Oaks
- Sanjay VadgamaSherman Oaks$3.3M
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.